LLY (Eli Lilly and Co) Investments And Advances : $3,200 Mil (As of Sep. 2024)

View and export this data going back to 1970. Start your Free Trial

What is Eli Lilly and Co Investments And Advances?

Eli Lilly and Co's Investments And Advances for the quarter that ended in Sep. 2024 was $3,200 Mil.

Eli Lilly and Co's quarterly Investments And Advances declined from Mar. 2024 ($3,087 Mil) to Jun. 2024 ($2,878 Mil) but then increased from Jun. 2024 ($2,878 Mil) to Sep. 2024 ($3,200 Mil).

Eli Lilly and Co's annual Investments And Advances declined from Dec. 2021 ($3,213 Mil) to Dec. 2022 ($2,902 Mil) but then increased from Dec. 2022 ($2,902 Mil) to Dec. 2023 ($3,052 Mil).

Eli Lilly and Co Investments And Advances Historical Data

The historical data trend for Eli Lilly and Co's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Investments And Advances Chart

Eli Lilly and Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Investments And Advances

Get a 7-Day Free Trial

1,962.40

2,966.80

3,212.60

2,901.80

3,052.20

Eli Lilly and Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Investments And Advances	Get a 7-Day Free Trial															2,691.70	3,052.20	3,086.90	2,877.60	3,200.20

Eli Lilly and Co Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Eli Lilly and Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NYSE:LLY) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

LLY:Mexico 1LLY:Italy LLY0:Germany LLY:Germany LLY:Germany LLY:Germany LLY:Germany LLYCL:Chile LLY:Switzerland LLY:Canada LILY34:Brazil LLY:Bulgaria LLYC:Austria LLY:Argentina

Address

Lilly Corporate Center, Indianapolis, IN, USA, 46285

Website

https://www.lilly.com

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Executives

Donald A Zakrowski	officer: Chief Accounting Officer	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Lilly Endowment Inc	10 percent owner	2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208
Johna Norton	officer: Senior VP, Global Quality	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Alonzo Weems	officer: SVP, ERM & CECO	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Patrik Jonsson	officer: SVP and Pres., Lilly Bio-Meds	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Anne E. White	officer: SVP & Pres-Lilly Oncology	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Eric Dozier	officer: EVP, HR & Diversity	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jackson P Tai	director
Mary Lynne Hedley	director	C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Marschall S Runge	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Naarden Jacob Van	officer: SVP, CEO LoxoONC, Pres LlyONC	C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Diogo Rau	officer: SVP & CIDO	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Edgardo Hernandez	officer: SVP & Pres., Mfg. Operations	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Kimberly H Johnson	director	C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005
Anat Ashkenazi	officer: SVP & CFO	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285